Reinhild Feuerstein

Reinhild Feuerstein

Auto-generated profile, based on publicly available information

Reinhild Feuerstein

University of Freiburg 5 Department of General and Visceral Surgery, Faculty of Medicine Freiburg, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
CLClaudia Lässle
Claudia Lässle
BMBernhard Mauerer
Bernhard Mauerer
LMLisa Marx
Lisa Marx
RFReinhild Feuerstein
Reinhild Feuerstein
HBHeidi Braumüller
Heidi Braumüller
RKRebecca Kesselring
Rebecca Kesselring
Obesity is a global epidemic characterized by energy disequilibrium, metabolic disorders, and fat mass development that greatly affect the health status of individuals. There is evidence that the intake of a high-fat diet and overweight are associated with the incidence of colorectal cancer (CRC). Metabolic surgery has been associated with improvements in obesity-related comorbidities and a reduction in the overall cancer risk. However, the underlying mechanism by which metabolic surgery reduces the risk of CRC remains unknown. To understand the antitumoral mechanism of bariatric surgery, we analyzed the development of CRC after Roux-en-Y gastric bypass (RYGB) surgery in an RYGB-CRC mouse model. Here, we showed that RYGB surgery substantially reduced primary tumorigenesis and prevented metastasis. This protective effect was mediated by bile acid (BA) exclusion from the proximal small intestine, leading to BA diversion in the preceding parts of the gastrointestinal tract and in circulation. The diverted BA profile in RYGB mice showed antitumoral and antimetastatic effects that were verified by BA exclusion of the proximal small bowel without the systemic metabolic installations of RYGB surgery by a cholecystointestinal shunt (CIS) surgery. RYGB surgery thus leads to reduced primary BAs and elevated secondary BAs in circulation. In a translational study involving patients with CRC with metachronous liver metastases, we confirmed that reduced primary BA concentrations in the serum were associated with prolonged time to metastasis, underscoring the critical role of BAs in CRC progression and metastatic development.

15 December 2019 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
RFReinhild Feuerstein
Reinhild Feuerstein
VGVitka Gres
Vitka Gres
NPNúria Elias Perdigó
Núria Elias Perdigó
SBSebastian Baasch
Sebastian Baasch
MFMirjam Freudenhammer
Mirjam Freudenhammer
PHPhilipp Henneke
Philipp Henneke
IFN-β essentially modulates the host response against mucocutaneous colonizers and potential pathogens, such as group B Streptococcus (GBS). It has been reported that the dominant signaling cascade driving IFN-β in macrophages (MΦ) in streptococcal infection is the cGAS–STING pathway, whereas conventional dendritic cells (DC) exploit endosomal recognition by intracellular TLRs. In this study, we revisited this issue by precisely monitoring the phenotypic dynamics in mixed mouse MΦ/DC cultures with GM-CSF, which requires snapshot definition of cellular identities. We identified four mononuclear phagocyte populations, of which two were transcriptionally and morphologically distinct MΦ–DC-like subsets, and two were transitional types. Notably, GBS induced a TLR7-dependent IFN-β signal only in MΦ-like but not in DC-like cells. IFN-β induction did not require live bacteria (i.e., the formation of cytolytic toxins), which are essential for IFN-β induction via cGAS–STING. In contrast to IFN-β, GBS induced TNF-α independently of TLR7. Subsequent to the interaction with streptococci, MΦ changed their immunophenotype and gained some typical DC markers and DC-like morphology. In summary, we identify IFN-β formation as part of the antistreptococcal repertoire of GM-CSF differentiated MΦ in vitro and in vivo and delineate their plasticity. Key Points Bone marrow GM-CSF culture gives rise to four distinct populations. GM-CSF MΦ can produce IFN-β. GBS-stimulated GM-CSF MΦ have the ability to adapt their phenotype to be more DC like.

1 February 2026 in Cancer Research Communications
Verified
Journal Article
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Combining anti-EGFR antibodies with BRAF/MEK/ERK pathway blockade opened new treatment options for BRAFV600E-driven colorectal cancer. Nevertheless, responses of these poor prognostic cancers are short-lived and heterogeneous, thereby highlighting the unmet need for novel concepts integrating targeted therapy and immuno-oncology. To this end, an immunocompetent mouse model with reliable disease onset and responding to clinically relevant drugs is essential but unavailable. In this study, we generated three cell lines from peritoneal metastases originating from orthotopically transplanted organoids carrying BrafV600E, Trp53R172H, and Apc mutations and characterized their ground state and responses to targeted therapy compounds in detail by RNA sequencing, whole-exome sequencing, and various functional assays. Interestingly, these so-called NaJa lines displayed distinct differentiation states and responses to the clinically relevant RAF inhibitors (RAFi) encorafenib and exarafenib, thereby resembling the clinical heterogeneity of BRAFV600E-driven colorectal cancer. RAFi resistance was overcome by the EGFR family inhibitor afatinib. RAFis also influenced the expression of the antigen presentation machinery, cytokines, and other immunomodulatory factors. Upon retransplantation into syngeneic mice, all NaJa lines established aggressive tumors with distinct tumor microenvironments matching their differentiation states. Thus, the NaJa lines provide a unique tool to study tumor heterogeneity, drug resistance, and the interplay between tumor, stroma, and immune cells in BRAFV600E-driven colorectal cancer. Significance: We present three newly isolated syngeneic BRAFV600E-driven colorectal cancer cell lines with distinct in vitro and in vivo phenotypes. They differ in their response to drug treatments, resemble patient tumor heterogeneity, and enable efficient tumor growth in immunocompetent mice for tumor-immune microenvironment studies.

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
NaJa cells differ in their response to drug treatment. A, Colony formation assay of NaJa cells treated with vemurafenib (V), encorafenib (E), and trametinib (T) at the indicated concentrations for 10 days. Shown is a representative result from three biological replicates. B–D, Quantification of the data shown in A. Data are presented as the mean ± SD and were normalized to the DMSO control (n = 3). Statistical significance was calculated using one-way ANOVA and Dunnett multiple comparisons test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. E, Phospho-RTK array of NaJa cells treated with 1 μmol/L vemurafenib (Vem), 0.5 μmol/L encorafenib (Enco), or 50 nmol/L trametinib (Tram) for 5 days. Shown are the log2 FCs of treated cells versus DMSO control. Array membranes and cell line specific heatmaps are displayed in Supplementary Fig. S7. F, Western blot showing the effect of a 5-day treatment of the NaJa cells on various signaling pathways. G, Western blot and quantification of HER2 and HER3 (n = 4). Basal EGFR expression was quantified based on data in (F), and five additional biological replicates normalized to the internal loading control. Data are presented as the mean ± SD and were normalized to NaJa-F for comparison. Statistical significance was calculated using one-way ANOVA and Tukey multiple comparisons test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. H, Bulk RNA-seq of NaJa cells treated with 0.5 μmol/L encorafenib for 1 day or 5 days showing upregulation (red) or downregulation (blue) of ERK target genes and the adjusted P value (bubble size).

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Supplementary Figure S7 shows the membranes from the phospho-RTK array of NaJa cells and detailed cell line specific heatmaps.

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
List of antibodies used in this study